Table 2. Summary of FDA approved biologics in pediatric psoriasis.

Adapted from Fortina et al. [12]

TB: tuberculosis; HCV: Hepatitis C virus; HBV: Hepatitis B virus

DESCRIPTION	ETANERCEPT	USTEKINUMUMAB
FDA approval for Pediatric moderate to severe Psoriasis	yes	yes
Age	≥6 years	≥12 years
Working Mechanism	human fusion protein which combines with a soluble fusion protein of TNF-α	A human monoclonal antibody which binds to p40 Subunit of IL 12-23
Route of administration	subcutaneous	subcutaneous
Recommended baseline monitoring parameters	TB, HIV, HCV, HBV screening incl: chest radiographs	TB, HIV, HCV, HBV screening  incl: chest radiographs
Recommended dose	0.8 mg/kg weekly . if ≥ 63 kg, 50 mg.	0.75 mg/kg/dose (<60 kg).  45 mg (60 to ≤ 1oo kg). 90 mg (>100 kg)  by week 0, 4, and every 12 weeks.
Absolute contraindication	Active infections including active TB, hepatitis	Active infections including active TB, hepatitis
Adverse effects	Primary AE (injection site reaction), Infections	Primary AE (injection site reaction), Infections